Precigen (NASDAQ:PGEN) Receives Buy Rating from HC Wainwright

Precigen (NASDAQ:PGEN)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $4.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 387.75% from the stock’s previous close. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at $0.01 EPS, FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.

PGEN has been the topic of a number of other reports. JMP Securities decreased their target price on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 15th. StockNews.com upgraded Precigen to a “sell” rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Precigen has an average rating of “Hold” and a consensus target price of $7.00.

Precigen Stock Performance

Shares of PGEN stock opened at $0.82 on Friday. Precigen has a fifty-two week low of $0.78 and a fifty-two week high of $1.93. The stock’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.24.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $1.28 million. Precigen had a negative return on equity of 112.05% and a negative net margin of 3,521.68%. On average, equities analysts predict that Precigen will post -0.44 earnings per share for the current year.

Institutional Trading of Precigen

Several hedge funds have recently made changes to their positions in the company. EntryPoint Capital LLC purchased a new stake in shares of Precigen during the 1st quarter valued at approximately $31,000. Traphagen Investment Advisors LLC purchased a new stake in Precigen in the third quarter valued at $29,000. Stifel Financial Corp lifted its stake in shares of Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 13,823 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 18,097 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.